http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109288831-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-015 |
| filingDate | 2018-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109288831-B |
| titleOfInvention | Docetaxel and elemene molecular compatible pharmaceutical composition and application thereof |
| abstract | The invention discloses a docetaxel and elemene molecular compatible pharmaceutical composition and application thereof, wherein the mass ratio of docetaxel to elemene is 20-1000. The composition can be used for treating breast cancer, lung adenocarcinoma, colon cancer, gastric cancer and prostate cancer, and especially has good curative effect on taxane drug-resistant breast cancer, taxane drug-resistant lung adenocarcinoma and taxane drug-resistant colon cancer; the molecular compatibility pharmaceutical composition is applied to the preparation of drugs for treating taxane drug-resistant tumors, has obvious paclitaxel drug-resistant effect, can also obviously reduce toxicity, and greatly relieves the pain of tumor patients. |
| priorityDate | 2018-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.